{"id":130312,"date":"2026-01-09T07:51:07","date_gmt":"2026-01-09T07:51:07","guid":{"rendered":"https:\/\/www.europesays.com\/se\/130312\/"},"modified":"2026-01-09T07:51:07","modified_gmt":"2026-01-09T07:51:07","slug":"ny-studieframgang-for-eli-lillys-fetmapreparat","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/130312\/","title":{"rendered":"Ny studieframg\u00e5ng f\u00f6r Eli Lillys fetmapreparat"},"content":{"rendered":"<p>Det amerikanska l\u00e4kemedelsbolaget Eli Lilly uppn\u00e5dde sitt prim\u00e4ra m\u00e5l i fas 3b-studien Together-Psa vid behandling av patienter med psoriasisartrit (Psa) och fetma samt med minst en samsjuklighet . Utfallet efter 36 veckor visade p\u00e5 en b\u00e4ttre effektivitet (superiority) f\u00f6r fetmal\u00e4kemedlet Zepbound i kombination med Taltz j\u00e4mf\u00f6rt med enbart behandling med Taltz. Studien omfattade 271 patienter. Det framg\u00e5r av ett pressmeddelande.<\/p>\n","protected":false},"excerpt":{"rendered":"Det amerikanska l\u00e4kemedelsbolaget Eli Lilly uppn\u00e5dde sitt prim\u00e4ra m\u00e5l i fas 3b-studien Together-Psa vid behandling av patienter med&hellip;\n","protected":false},"author":2,"featured_media":130313,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-130312","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115864055634534590","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/130312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=130312"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/130312\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/130313"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=130312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=130312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=130312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}